From: Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment
HSA-ATO NPs
Mean ± SD (n = 3)
Size (nm)
164.5 ± 10.3
PDI
0.326 ± 0.02
Ζeta potential (mV)
− 12.13 ± 1.05
Drug loading (%)
8.70 ± 1.92
EE (%)
87.2 ± 2.5